好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

First Deployment of a Portable, Bedside, Low-Field Magnetic Resonance Imaging Solution for Artificial Intelligence Based Application
Neuro Trauma, Critical Care, and Sports Neurology
S61 - Neurocritical Care: Cerebrovascular Disease (1:00 PM-1:12 PM)
001
To demonstrate proof-of-concept for a portable, bedside magnetic resonance imaging (MRI) in acute brain injury using artificial intelligence (AI) based determination of mass effect (ME).
High-field MRI requires transport of patients to an imaging suite for data acquisition. Advances in low-field MRI have made it possible to obtain useful imaging at the bedside. While human reader assessment of midline shift (MS) is a conventional measure of mass effect (ME) in brain injury, here we use portable MRI based 3-D images of the brain to assess mass effect using artificial intelligence.
We studied 66 patients with acute brain injury admitted to an intensive care unit who underwent portable 64 mT MRI at the bedside.  Three human annotators marked midline shift on T2-weighted or steady-state free precession (SSFP) sequences at the falx, septum, and pineal. A deep learning model was applied using a U-Net neural network and implemented in TensorFlow. Baseline injury severity using National Institutes of Health Stroke Scale Score (NIHSS) and functional outcome at discharge were obtained from the medical record. Statistical analysis was performed in Python. Correlation analysis was done between individual and average scores of human-MS versus AI-ME. Human-MS and AI-ME was correlated against NIHSS.

Average human-MS correlated strongly with AI-ME (p=0.01). An average of 9 human-MS measures were required to achieve the level of significance of correlation of AI-ME, however. Individual human-MS ratings also correlated, but less significantly (p=0.03). Individual human-MS measures did not correlate to NIHSS (p=0.55). Average human-MS and AI-ME showed a trend toward correlation to NIHSS (p=0.11 and p=0.07, respectively).
These data demonstrate use of a portable MRI device at the bedside in patients with acute brain injury. Portable MR images can be ascertained and interpreted for clinically relevant outcomes such as mass effect using artificial intelligence methods, independent of a human reader.
Authors/Disclosures
Kevin N. Sheth, MD, FAAN (Yale UniversityDivision of Neuro and Critical Care)
PRESENTER 		Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care.
Bradley Cahn Mr. Cahn has nothing to disclose.
No disclosure on file
Jill T. Shah No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Matthew Yuen (Yale University) Mr. Yuen has nothing to disclose.
Mercy H. Mazurek (Harvard Medical School) Miss Mazurek has nothing to disclose.
Charles Matouk Charles Matouk has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Silk Road Medical. Charles Matouk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Microvention. Charles Matouk has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Navigantis.
Barbara S. Gordon-Kundu, MD An immediate family member of Dr. Gordon-Kundu has received personal compensation for serving as an employee of Ceretype .
No disclosure on file
Sam Payabvash Sam Payabvash has nothing to disclose.
Guido J. Falcone, MD (Yale School of Medicine) The institution of Dr. Falcone has received research support from NIH. The institution of Dr. Falcone has received research support from AHA.
Nils Petersen, MD (Yale University) The institution of Dr. Petersen has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Silkroad Medical. Dr. Petersen has received research support from NIH.
Joseph L. Schindler, MD (Yale University Department of Neurology) Dr. Schindler has received personal compensation for serving as an employee of Aeromics. Dr. Schindler has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Aeromics. Dr. Schindler has received stock or an ownership interest from Aeromics. Dr. Schindler has received publishing royalties from a publication relating to health care.
Emily J. Gilmore, MD (Yale University School of Medicine) Dr. Gilmore has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for carpl.ai. Dr. Gilmore has received personal compensation in the range of $0-$499 for serving as a Consultant for AAN. Dr. Gilmore has received research support from NIH.
David Y. Hwang, MD, FAAN (University of North Carolina School of Medicine) The institution of Dr. Hwang has received research support from NIH. The institution of Dr. Hwang has received research support from Neurocritical Care Foundation. Dr. Hwang has received publishing royalties from a publication relating to health care. Dr. Hwang has received personal compensation in the range of $10,000-$49,999 for serving as a Associate Medical Director with New England Donor Services.
Kevin Gobeske, MD (Yale School of Medicine, Neurology) Dr. Gobeske has nothing to disclose.
Jennifer A. Kim, MD (Yale University School of Medicine) Dr. Kim has nothing to disclose.
Lauren H. Sansing, MD Dr. Sansing has nothing to disclose.
Gordon Sze Gordon Sze has nothing to disclose.
Matthew Rosen Matthew Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for DeepSpin. Matthew Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Chipiron. Matthew Rosen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Synex Medical. Matthew Rosen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Nanalysis. Matthew Rosen has stock in Hyperfine. Matthew Rosen has stock in Q Bio. Matthew Rosen has stock in Vizma Life Sciences. Matthew Rosen has stock in Intact Data Services. The institution of Matthew Rosen has received research support from Imagion. Matthew Rosen has received intellectual property interests from a discovery or technology relating to health care.
W. T. Kimberly, MD, PhD (Massachusetts General Hospital) Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astrocyte Pharmaceuticals. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acasti Pharma. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hyperfine Inc.. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurotherapeutics. Dr. Kimberly has stock in Woolsey Pharmaceuticals. Dr. Kimberly has stock in Acasti Pharma. The institution of Dr. Kimberly has received research support from Biogen. The institution of Dr. Kimberly has received research support from NControl Therapeutics. The institution of Dr. Kimberly has received research support from NIH. The institution of Dr. Kimberly has received research support from American Heart Association. The institution of Dr. Kimberly has received research support from Hyperfine, Inc.. Dr. Kimberly has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file